Ctx Platforms - Israel

CTX-Platforms is a biotechnology company that is innovating a targeted protein delivery system for diagnosing and treating cancer. The system is based on a patent-pending synthetic molecule derived from scorpion venom, which is capable of penetrating both the blood-brain barrier and solid tumors outside the CNS. To serve as bio-carriers, the company is developing specific proteins derived from scorpion venom that express selective affinity to cancer tissues, high stability, and effective penetrability to the blood-brain barrier. CTX-Platforms holds intellectual property on the synthetic peptide that is based on a natural molecule from scorpion venom. This peptide has selective affinity to cancer cells, can penetrate the BBB, and has potential applications in therapeutics and diagnostics.